JAK2 and essential thrombocythemia: This difference cannot be explained solely by the higher prevalence of JAK2 mutations or by the higher allelic burden of JAK2 mutations that is characteristic of patients with PV, as there was no significant association between the mutational status of JAK2 and the reduction in NET formation markers following IFNα exposure in patients with ET.